Cargando…
Low-molecular-weight cyclin E: the missing link between biology and clinical outcome
Cyclin E, a key mediator of transition during the G(1)/S cellular division phase, is deregulated in a wide variety of human cancers. Our group recently reported that overexpression and generation of low-molecular-weight (LMW) isoforms of cyclin E were associated with poor clinical outcome among brea...
Autores principales: | Akli, Said, Keyomarsi, Khandan |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549170/ https://www.ncbi.nlm.nih.gov/pubmed/15318923 http://dx.doi.org/10.1186/bcr905 |
Ejemplares similares
-
A Novel Interaction Between HER2/neu and Cyclin E in Breast Cancer
por: Mittendorf, Elizabeth A., et al.
Publicado: (2010) -
The Serine Protease Inhibitor Elafin Maintains Normal Growth Control by Opposing the Mitogenic Effects of Neutrophil Elastase
por: Caruso, Joseph A., et al.
Publicado: (2014) -
LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers
por: Lulla, Amriti R., et al.
Publicado: (2021) -
PKC iota promotes ovarian tumor progression through deregulation of cyclin E
por: Nanos-Webb, Angela, et al.
Publicado: (2015) -
LMW-E/CDK2 Deregulates Acinar Morphogenesis, Induces Tumorigenesis, and Associates with the Activated b-Raf-ERK1/2-mTOR Pathway in Breast Cancer Patients
por: Duong, MyLinh T., et al.
Publicado: (2012)